Successful sequential therapy with rituximab and daratumumab for
refractory post-transplant immune thrombocytopenic purpura
Yuki Shino1, Katsutsugu Umeda1*,
Yoshinori Uchihara1, Kazuki Mitani1,
Keiji Tasaka1, Hideto Ogata1,
Hirokazu Kobushi1, Satoshi Saida1,
Itaru Kato1, Takeshi Yoshida1,
Atsushi Yokoyama1, Hidefumi
Hiramatsu1, Junko Takita1
1Department of Pediatrics, Graduate School of
Medicine, Kyoto University
*Correspondence to:
Katsutsugu Umeda, Department of Pediatrics, Graduate School of Medicine,
Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507,
Japan
Phone: +81-75-751-3290; Fax: +81-75-752-2361
E-mail address:umeume@kuhp.kyoto-u.ac.jp
Main text word count: 581 words
Figures: 1
Tables: 0
Short running head: Rituximab and daratumumab for post-HCT ITP
Keywords: immune thrombocytopenic purpura, immune-mediated
cytopenia, rituximab, daratumumab, hematopoietic cell transplantation